Clinical Trials Search
Phase 2 Study of Ceritinib in Patients with Unresectable Melanoma
The main purpose of this study is to determine the benefit of a drug named ceritinib (ZYKADIA) in patients who have progressed on prior melanoma therapy.
PRIMARY OBJECTIVE: To determine the overall response rate (ORR) of ceritinib (per RECIST 1.1 criteria). ORR will be defined by proportion of patients who have achieved a complete response (CR) or partial response (PR) per RECIST v1.1 criteria.